Fidelity Increases TTH Holdings by 28.6%
Thats an increase of 28.6% or 664,034 shares......
EARLY WARNING REPORT UNDER
THE ALTERNATIVE MONTHLY REPORTING SYSTEM
OF NATIONAL INSTRUMENT 62-103
1. Name and address of the eligible institutional investor:
Fidelity Management & Research Company ("FMR Co.")
82 Devonshire Street
Boston, MA, 02109
FMR Co., and certain other relevant affiliates and associates are sometimes
hereinafter collectively referred to as “Fidelity.”
2. Name of the reporting issuer:
Transition Therapeutics Inc.
3. Period for which the report is filed:
Period ended 11/30/2007
4. Net increase or decrease in the number or principal amount of securities, and in
the eligible institutional investor’s security holding percentage in the class of
securities, since the last report filed by the eligible institutional investor under
the early warning requirements:
Since Fidelity’s last report filed on 2/12/2007, Fidelity’s holdings have increased
by 664,034 shares. This represents a net increase of 28.61% of the shares held by
Fidelity.
5. Designation and number or principal amount of securities and the eligible
institutional investor’s security holding percentage in the class of securities at the
end of the month for which the report is made:
Fidelity now holds 2,985,301 common shares representing approximately
12.99% of the outstanding shares of that class.
6. Designation and number or principal amount of securities and the percentage of
outstanding securities of the class of securities referred to above over which:
(i) the eligible institutional investor, either alone or together with any joint actors,
have ownership and control:
N/A.
(ii) the eligible institutional investor, either alone or together with any joint
actors, have ownership but control is held by other entities other than the eligible
institutional investor or any joint actor:
N/A.
(iii) the eligible institutional investor, either alone or together with any joint
actors, have exclusive or shared control but does not have ownership:
2,985,301 common shares representing approximately 12.99% of the outstanding
shares of that class.
7. Purpose of the eligible institutional investor and any joint actors in acquiring or
disposing of ownership of, or control over, the securities, including any future
intention to acquire ownership of, or control over, additional securities of the
reporting issuer:
The common shares of Transition Therapeutics Inc. were acquired in the
ordinary course of business, for investment purposes only and not with the
purpose of exercising control or direction over Transition Therapeutics Inc.
Fidelity may from time to time, on behalf of funds or accounts it manages,
acquire additional common shares, dispose of some or all of the common shares
they hold or continue to hold common shares.
8. General nature and the material terms of any agreement, other than lending
arrangements, with respect to securities of the reporting issuer entered into by
the eligible institutional investor, or any joint actor, and the issuer of the
securities or any other entity in connection with any transaction or occurrence
resulting in the change in ownership or control giving rise to the report,
including agreements with respect to the acquisition, holding, disposition or
voting of any of the securities:
N/A.
9. Names of any joint actors in connection with the disclosure required by
Appendix G of National Instrument 62-103:
N/A.
10. If applicable, a description of any change in any material fact set out in a
previous report by the eligible institutional investor under the early warning
requirements:
N/A.
11. Eligibility to file reports under the alternative monthly reporting system:
Fidelity is eligible to file this report either under the alternative monthly
reporting system of National Instrument 62-103.
12. Declaration:
The filing of this report is not an admission that any entity named in this report
owns or controls any securities or is a joint actor with another named entity.
DATED 12/7/2007
By: /s/“Eric D. Roiter”
Name: Eric D. Roiter
Title: Senior V.P. & General Counsel - FMR Co.